Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ASPIFOX 20 MG/100 MG CAPSULAS DURAS - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/ASPIFOX 20 MG/100 MG CAPSULAS DURAS

Approved

STANDARD

ASPIFOX 20 MG/100 MG CAPSULAS DURAS

Teva B.V.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Sep 7, 2020
Approval ID: f030d91de926e61f
Company: Teva B.V.
Type: Standard

Approval Details

Approval Id: f030d91de926e61f
Drug Cima Aemps Name: ASPIFOX 20 MG/100 MG CAPSULAS DURAS
Register Number: 85381
Holder Company Name: Teva B.V.
Marketing Company Name: Teva Pharma S.L.U.
Holder Company Detail Path: /organization/teva-pharma-b-v
Authorization Date: 2020-09-07
Dosage Form: CÁPSULA DURA
Dose: 20 mg/100 mg
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: Yes
Company Name: Teva B.V.
Company Detail Path: /organization/teva-pharma-b-v

Company Information

Pharmaceutical Company Name: Teva Pharma B.V.
Country Name: Netherlands
City Name: haarlem,noord-holland,country_nl
Address: Swensweg 5
Website: http://www.tevapharm.com

Active Ingredients

ROSUVASTATINA CALCICA

20,8 mg

ACETILSALICILICO ACIDO

100 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Sep 7, 2020

Approval ID

f030d91de926e61f

Type

Standard

Back to CIMA-AEMPS Approvals